We are live on ! Find out more
BNTC icon

Benitec Biopharma
BNTC

3 hedge funds and large institutions have $414K invested in Benitec Biopharma in 2016 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $386K → $414K (+$28K)

0% more funds holding

Funds holding: 3 → 3 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$24K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$30.1K
2
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$389K -$30.1K -79 -7%
Citadel Advisors
2
Citadel Advisors
Florida
$25K +$24K +63 New
TRCT
3
Tower Research Capital (TRC)
New York
– -$1K -4 Closed

BNTC Hedge Fund Activity: Q4 2016 in Review

3 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q4 2016, worth a combined $414K — up 7.3% from $386K a quarter earlier.

Fund positioning in BNTC was balanced in Q4 2016: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $24K. The largest seller was Sabby Management, cutting an estimated $30.1K.

  • 3 institutional investors held Benitec Biopharma (BNTC) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $414K of Benitec Biopharma stock for Q4 2016, up 7.3% quarter-over-quarter.
  • 1 fund opened new Benitec Biopharma positions in Q4 2016 and 1 closed out, a net change of 0 holders.
  • The largest Benitec Biopharma buyer in Q4 2016 was Citadel Advisors, an estimated $24K added.
  • The largest Benitec Biopharma seller in Q4 2016 was Sabby Management, an estimated $30.1K sold.

Based on aggregated 13F filings for Q4 2016.